Prescription for Better Access Resonate Recordings https://resonaterecordings.com © 2026 Prescription for Better Access Mark Hansan and Dr. Scott Howell en-us Tue, 14 Apr 2026 11:23:45 +0000 Tue, 14 Apr 2026 11:23:45 +0000 https://www.prescriptionforbetteraccess.com https://storage.googleapis.com/com-resonaterecordings-public/cover-art/0nYGq6bPFZqCCTj5j0ikYZqAFM3BuqMRjjBwq7FJ.jpg Prescription for Better Access https://www.prescriptionforbetteraccess.com Mark Hansan and Dr. Scott Howell false episodic Mark Hansan and Dr. Scott Howell Mark Hansan and Dr. Scott Howell comments@prescriptionforbetteraccess.com No false Spotlight on Rare Disease: A Conversation with Alexander Hardy, President and CEO, BioMarin Spotlight on Rare Disease: A Conversation with Alexander Hardy, President and CEO, BioMarin In this episode, we sit down with Alexander Hardy, President and CEO of BioMarin, to talk about his path to leading one of the world's premier rare disease companies. Alexander reflects on his expe... full ab4d3911-2366-41e5-839e-be700b8e2b21 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/ab4d3911-2366-41e5-839e-be700b8e2b21 In this episode, we sit down with Alexander Hardy, President and CEO of BioMarin, to talk about his path to leading one of the world's premier rare disease companies. Alexander reflects on his experience across small molecules, biologics, oncology, and rare diseases, and how his work in access and patient services has shaped his thinking about leadership. We discuss the policy environment coming out of Washington — including the IRA and other pricing reforms — and how those factors influence long-term innovation and investment decisions. We also explore the real-world challenges facing rare disease patients, employer concerns about high-cost therapies, and what needs to change over the next five years to improve access and affordability.

Questions or comments? Email comments@prescriptionforbetteraccess.com. Find us on X, LinkedIn, YouTube, and Threads.

]]> Mon, 30 Mar 2026 09:00:00 +0000 2329 false false A Legal Perspective on PBM Reform and FTC Enforcement A Legal Perspective on PBM Reform and FTC Enforcement   In this episode of Prescription for Better Access, we’re joined by William (Bill) Sarraille, a legal expert on drug access and reimbursement. He discusses two developments shaping the p... full f9e9314a-112b-4c07-a321-b89f249ff593 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/f9e9314a-112b-4c07-a321-b89f249ff593  

In this episode of Prescription for Better Access, we’re joined by William (Bill) Sarraille, a legal expert on drug access and reimbursement. He discusses two developments shaping the pharmacy benefit landscape: the FTC’s enforcement action involving Express Scripts and PBM reforms in the Consolidated Appropriations Act of 2026. Bill explains what these policy changes could mean for benefit design, drug coverage, employer-sponsored plans, and transparency in the PBM market. We also explore potential impacts on formularies, utilization management, contracting practices, and patient out-of-pocket costs, along with possible unintended consequences for employers, manufacturers, and patients seeking timely and affordable access to medicines.

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Follow us on X, LinkedIn, YouTube, and Threads.

]]> Tue, 10 Mar 2026 09:00:00 +0000 2500 false false From Policy to the Employer Front Lines: A Conversation with Dan Mendelson of Morgan Health From Policy to the Employer Front Lines: A Conversation with Dan Mendelson of Morgan Health Employers sit at the center of the U.S. health system as the primary funders of coverage for more than 150 million Americans, yet they struggle with rising costs, fragmented vendors, and uneven out... full 880a4763-278a-4071-9617-f60cedb6ed75 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/880a4763-278a-4071-9617-f60cedb6ed75 Employers sit at the center of the U.S. health system as the primary funders of coverage for more than 150 million Americans, yet they struggle with rising costs, fragmented vendors, and uneven outcomes. In this episode, we talk with Dan Mendelson, MPP, CEO of Morgan Health at JPMorgan Chase & Co. and Founder and former CEO of Avalere Health. We explore his journey from health policy to now leading Morgan Health’s efforts to improve the quality, affordability and equity of employer-sponsored healthcare. We’ll learn how Morgan Health evaluates the employer market, where they’re placing investment bets, and how they are testing new care models inside JPMorgan’s own benefit. We then turn to Washington: Dan shares his take on the policy currents that matter most for employers and innovators over the next few years.

Questions or comments?

Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.




]]> Fri, 09 Jan 2026 10:00:00 +0000 2341 false false Understanding the Impact of the Accelerated Approvals Program Understanding the Impact of the Accelerated Approvals Program The FDA’s Accelerated Approval Program (AAP) aims to bring promising, potentially life-saving medicines to patients sooner by allowing approvals based on surrogate endpoints while requiring timely ... full 438137e2-91c8-45d2-a5c5-6920c363cb49 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/438137e2-91c8-45d2-a5c5-6920c363cb49 The FDA’s Accelerated Approval Program (AAP) aims to bring promising, potentially life-saving medicines to patients sooner by allowing approvals based on surrogate endpoints while requiring timely confirmatory evidence. In this episode, we speak with Bridget Doherty, MPH, MS (Johnson & Johnson Innovative Medicine), and Jeff Allen, PhD (Friends of Cancer Research). Bridget discusses her team’s review of the AAP’s real-world impact, showing that hundreds of thousands of meaningful life-years have been gained for patients. Jeff shares findings from work strengthening biomarkers as reliable surrogate endpoints—helping define when increased speed can still preserve scientific rigor. We also explore the core access challenge: how payer coverage and utilization management help or hinder patients the AAP is designed to serve. We close with practical policy steps to ensure that earlier regulatory access truly leads to better outcomes for people who need treatments most.

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media: X, LinkedIn, YouTube, and Threads.

]]> Tue, 25 Nov 2025 10:00:00 +0000 false false Charting a Path Forward for More Patient-Centered Value Assessment Methods 32 Charting a Path Forward for More Patient-Centered Value Assessment Methods In this episode, we talk with Richard Xie, Senior Health Economist at RA Capital, and Gunnar Esiason, Senior Director of Patient Engagement at Raven (RA Capital Ventures), about value frameworks in... full cbb3df56-8f9c-45fd-92b9-d5a057cc4510 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/cbb3df56-8f9c-45fd-92b9-d5a057cc4510 In this episode, we talk with Richard Xie, Senior Health Economist at RA Capital, and Gunnar Esiason, Senior Director of Patient Engagement at Raven (RA Capital Ventures), about value frameworks in pharma. We unpack how Generalized Cost-Effectiveness Analysis (GCEA) builds on traditional Cost-Effectiveness Analysis (CEA) and differs from ICER’s model. The conversation explores what these approaches mean for pricing, access, and patient voice—especially in rare and high-innovation settings.

Through the Cidara CD388 flu drug case, we discuss how assumptions shape value and trade-offs from manufacturer and patient perspectives. The episode highlights how evidence, incentives, and outcomes align—or conflict—in today’s system, and what reforms could better connect value frameworks to affordability and equitable access.

Questions or comments? Email comments@prescriptionforbetteraccess.com.

Follow us on X, LinkedIn, YouTube, and Threads.

]]> Fri, 17 Oct 2025 09:00:00 +0000 false false IRA, Part D Redesign & the Future of Drug Access: A Conversation with Jon Blum, Former CMS Principal Deputy Administrator and COO 31 IRA, Part D Redesign & the Future of Drug Access: A Conversation with Jon Blum, Former CMS Principal Deputy Administrator and COO In this episode, former CMS official Jon Blum reflects on the evolution and impact of the IRA’s drug provisions—from foundational drivers and political trade-offs to how 2026 Part D redesign and th... full db86efba-82e9-4a6e-ba43-d6b6e6e3a5f8 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/db86efba-82e9-4a6e-ba43-d6b6e6e3a5f8 Thu, 18 Sep 2025 09:00:00 +0000 false false The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference 30 The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: W... full 78cbd66e-6787-45ae-9b90-f06b8c7233f5 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/78cbd66e-6787-45ae-9b90-f06b8c7233f5 At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation.

Questions? Email comments@prescriptionforbetteraccess.com.
Follow us on X, LinkedIn, YouTube, and Threads.

]]> Thu, 17 Jul 2025 09:00:00 +0000 false false The Domino Effect: 2025 Trends in Specialty Drug Benefits Report 29 The Domino Effect: 2025 Trends in Specialty Drug Benefits Report Specialty drug benefit design isn't just one decision — it triggers a domino effect impacting employer and health plan costs, patient access, care delivery and patient cost-sharing. In this e... full 61e4ab22-fb2d-4a8a-a2a6-6427ad07d45c https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/61e4ab22-fb2d-4a8a-a2a6-6427ad07d45c Specialty drug benefit design isn't just one decision — it triggers a domino effect impacting employer and health plan costs, patient access, care delivery and patient cost-sharing. In this episode, we unpack PSG’s latest research on how employers and health plans are rethinking specialty strategies amid rising pressure: cost management as a top priority, movement toward rebate alternatives, shifting site of care models, and evolving approaches to affordability and utilization management. Our guests break down where the biggest shifts are happening, what’s still missing, and how smarter benefit design can create better outcomes across the healthcare system.

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Wed, 21 May 2025 09:00:00 +0000 3036 false false Inside the Cost Curve: An Interview with Brian Reid 28 Inside the Cost Curve: An Interview with Brian Reid &lt;p&gt;In this episode, we interview Brian Reid, the founder of Reid Strategic and the creator and editor of our favorite industry newsletter, the Cost Curve. Brian shares his journey to create t... full 70b05daa-d959-41ea-a678-7c46faf26026 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/70b05daa-d959-41ea-a678-7c46faf26026 <p>In this episode, we interview Brian Reid, the founder of Reid Strategic and the creator and editor of our favorite industry newsletter, the Cost Curve. Brian shares his journey to create the Cost Curve and how he navigates the onslaught of information to identify the most important issues of the day. We also get his take on what he calls the highest &ldquo;importance-to-attention&rdquo; healthcare stories, highlighting critical topics that are undercovered related to their significance. We also get the opportunity to understand his perspectives on the threats to innovation, the risks to patient affordability programs, and what all of us should be doing to be better healthcare consumers.</p>

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Thu, 17 Apr 2025 09:00:00 +0000 2710 false false Value in Prescription Drugs – What Does It Really Mean? 27 Value in Prescription Drugs – What Does It Really Mean? In this episode, we explore the complex and often debated concept of value in prescription drugs. They discuss how different stakeholders&mdash;payers, manufacturers, providers, regulators, and pat... full e945af6d-723b-4b2c-9fde-d57c641a1fbd https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/e945af6d-723b-4b2c-9fde-d57c641a1fbd In this episode, we explore the complex and often debated concept of value in prescription drugs. They discuss how different stakeholders—payers, manufacturers, providers, regulators, and patients—define value, and how methodologies like health technology assessments (HTA) and cost-effectiveness analyses shape drug pricing and access. With insights from leading experts, the conversation examines the controversies surrounding value-based pricing, including the role of real-world evidence, quality-adjusted life years (QALYs), and innovation incentives. Can we strike a balance between affordability, innovation, and patient access? And what does the future hold for value-based drug pricing in the U.S.? Tune in for a deep dive into one of the most critical issues in healthcare today.

  • Daniel Ollendorf, Chief Scientific Officer and Director of HTA Methods and Engagement
  • Lou Garrison, Professor Emeritus at University of Washington CHOICE

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

]]> Thu, 20 Mar 2025 09:00:00 +0000 3090 false false An interview with Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER) 26 An interview with Sarah Emond, MPP, President and CEO, Institute for Clinical Economic Review (ICER) In this episode, we interview Sarah Emond, MPP, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah joined ICER over 15 years ago as Chief Operating Officer and was ap... full 0cd6195d-7ea5-499a-a5be-e92cc7176057 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/0cd6195d-7ea5-499a-a5be-e92cc7176057 In this episode, we interview Sarah Emond, MPP, President and CEO of the Institute for Clinical and Economic Review (ICER). Sarah joined ICER over 15 years ago as Chief Operating Officer and was appointed to lead the organization following the retirement of Dr. Steven Pearson. Sarah outlines her vision for ICER and the priorities for strengthening the framework and collaboration to achieve their mission of evaluating the comparative effectiveness of new medicines. Sarah also discusses ICER’s efforts to expand patient engagement and the evaluation of payers to ensure fair access to medicine.

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

]]> Thu, 20 Feb 2025 10:00:00 +0000 2614 false false 2025 Outlook with Stacie Dusetzina, Ph.D., Vanderbilt University 25 2025 Outlook with Stacie Dusetzina, Ph.D., Vanderbilt University In this episode, we sit down with Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center to discuss the critical healthcare and policy trends shaping 2025. Fr... full de64d454-425f-4013-b6b5-c9de66404782 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/de64d454-425f-4013-b6b5-c9de66404782 In this episode, we sit down with Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center to discuss the critical healthcare and policy trends shaping 2025. From shifts in federal leadership to the evolving impact of the Inflation Reduction Act, our guest provides expert insights on what to expect in drug pricing, health insurance, and patient access in the coming year. We explore how the public and private sectors are addressing affordability challenges and highlight innovative approaches to improve access to essential medications. With a focus on the future, this conversation offers a thoughtful outlook on the policies and market dynamics set to redefine healthcare in 2025.

Stacie Dusetzina, Ph.D., Vanderbilt University

Vanderbilt University Medical Center

A primer on copay accumulators, copay maximizers, and alternative funding programs

CMS 
FDA

IRA

Medicare Part D

Pharmacy Benefit Managers (PBMs)

Medicaid

CMMI’s Medicaid group negotiation 

COVID-19

Statins

PCSK9 inhibitors

Imatinib

340B Drug Pricing Program

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Wed, 18 Dec 2024 10:00:00 +0000 2861 false false Cell and Gene Therapy Access Challenges 24 Cell and Gene Therapy Access Challenges In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene thera... full ad17c8c2-4d3a-4402-a78f-54fa2bc894bd https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/ad17c8c2-4d3a-4402-a78f-54fa2bc894bd In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies. 

Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health
Eric Faulkner, President, Passage Health Associates
ADVI Health
Alliance for Regenerative Medicine
ARPA-H
Bespoke Gene Therapy Consortium
Blue Bird Bio
Blue Cross Blue Shield
Medicare DRG Rates
NICE (National Institute for Health and Care Excellence)
Novartis
Passage Health Associates
REMS Program
Single Case Agreements
Spark Therapeutics

Medical terminology referenced in this episode:




]]> Wed, 04 Dec 2024 10:00:00 +0000 3186 false false Global vs. US Drug Pricing and Market Access 23 Global vs. US Drug Pricing and Market Access In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves i... full baa11570-894a-43a3-bb5e-0db4c73ae2bd https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/baa11570-894a-43a3-bb5e-0db4c73ae2bd In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves into the distinct approaches taken by government vs. private markets, examining how regulatory environments, pricing controls, and reimbursement processes impact patient access to innovative therapies. We explore the challenges each approach faces, from cost pressures to affordability and access, and how they balance the interests of patients, governments, and pharmaceutical companies. Join us for a deep dive into how the global healthcare landscape is evolving and what lessons can be learned.

Nikos Maniadakis, Ph.D., Professor, Health Management & Policy, University of West Attica
Kimberly Baldwin, Senior Vice President, Value & Access, Ipsen Biopharmaceuticals
Fauzea Hussain, Vice President, Public Policy, McKesson
CMS (Centers for Medicare & Medicaid Services)
European Medicines Agency
Health technology assessments (HTAs)
IRA (Inflation Reduction Act)
Medicaid
Medicare
National Institute of Clinical Excellence (NICE)
NCCN guidelines
P&T committee (Pharmacy and Therapeutics Committee)
PAP (Patient Assistance Program)
Part B (Medicare)
Part D (Medicare)
Pharmacy Benefit Managers (PBMs)
Quality-Adjusted Life Years
Tricare
Veterans Administration
Medical terminology referenced in this episode:

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.




]]> Tue, 22 Oct 2024 09:00:00 +0000 3265 false false 22. Honoring the Work of Healthcare Advocates 22 22. Honoring the Work of Healthcare Advocates In this episode, we explore the evolving role of healthcare and patient advocates and how this profession has become an essential part of the healthcare system. We begin by defining what a healthca... full 9ded702c-0e28-4c9b-9ae0-b44b6b806731 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/9ded702c-0e28-4c9b-9ae0-b44b6b806731 In this episode, we explore the evolving role of healthcare and patient advocates and how this profession has become an essential part of the healthcare system. We begin by defining what a healthcare advocate is and tracing the development of the profession over the years. Key milestones are discussed, such as establishing codes of ethics, training, and certification processes. We also share real-world examples of how advocates help patients navigate the complexities of healthcare, making a measurable impact on patient outcomes. The discussion covers the scale of advocacy in the U.S., examining the roles of professional advocates compared to family members and volunteers. We also address how advocates are helping patients overcome barriers to accessing and affording medicines. Finally, we look to the future of advocacy, discussing potential healthcare reforms, the impact of technology, and practical advice for patients seeking an advocate in today's challenging healthcare environment.

Rachel Westlake, Managing Director, Coalition of Health Care Advocacy Organizations
Danielle Marshall, Executive Director, Patient Advocate Certification Board
Fred Larbi, Chief Operations Officer, HealthWell Foundation
CHCAO
Patient Advocate Cerification Board
Healthwell Foundation
Greater National Advocates
NAHAC
HealthAdvocateX
Umbra
Solace 

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Thu, 12 Sep 2024 09:00:00 +0000 2691 false false Evolution of PBM's 21 Evolution of PBM's In this episode, we explore the evolution and future of the Pharmacy Benefit Management (PBM) industry with insights from two seasoned pharma managed care executives. We discuss the early role of P... full 6f9d7290-0671-46ef-82f1-2aa808bbf324 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/6f9d7290-0671-46ef-82f1-2aa808bbf324 In this episode, we explore the evolution and future of the Pharmacy Benefit Management (PBM) industry with insights from two seasoned pharma managed care executives. We discuss the early role of PBMs, their acquisition by pharmaceutical companies, and subsequent industry consolidation. We examine how vertical integration of the PBMs transformed their business model, including the restricted formularies that gave rise to rebates. We also address evolving PBM-manufacturer relationships, the effects of public scrutiny, and predictions for key trends. Join us for a comprehensive look at the past, present, and future of PBMs, focusing on the changes needed to better serve patients.

Steve Stefano, Managing Director, ReprizioRx 

Steve.Stefano@repriziorx.com

Bill Leonard, Managing Director, ReprizioRX

wjl@repriziorx.com

ReprizioRX

PBMs

IPA model HMO

Medco

Metro Containment Services

Medicare Catastrophic Coverage Act of 1988

Merck

SmithKline Beecham

Eli Lilly

340B

NDC blocks

Group Purchasing Organizations (GPOs) 

Medicare

United Healthcare

FTC

CostPlusDrugs


Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

]]> Tue, 20 Aug 2024 09:00:00 +0000 2725 false false How Access Challenges Impact the Drug Development Pipeline 20 How Access Challenges Impact the Drug Development Pipeline In this episode, we dive into the pharmaceutical industry's research and drug development side and the real threat that today&rsquo;s access and affordability challenges and policies pose to innova... full fcae9b2e-1840-4535-a90f-90d776c8a58c https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/fcae9b2e-1840-4535-a90f-90d776c8a58c In this episode, we dive into the pharmaceutical industry's research and drug development side and the real threat that today’s access and affordability challenges and policies pose to innovation. While innovation often starts in universities with government support, biotech, and pharma companies take on the tough, costly job of clinical trials, development, and approval of new drugs. Investment dollars are limited, only the most promising projects get funded, with an expectation there will be a return. However, our current drug payment process and policies like the IRA have added new considerations for investors, risking fewer new drugs being developed. Without changes, patients could face the closing of our nation's medicine cabinet, with fewer new treatments available. This would be an outcome that would be catastrophic for all of us.

Erin Mistry, EVP and Chief Commercial Officer, Cormedix, Inc.


Imran Nasrullah, JD., formerly VP & US Head of BD&L at Bayer, and now Founder, SNAP Life Sciences

Research and development (R&D)

FDA

CF Foundation

Vertex

NIH

AMR (antimicrobial resistance)

The Pasteur Act

HIV

Malaria

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.

Genentech

Genzyme (Now Sanofi)

Medicare

IRA (Inflation Reduction Act)

COVID-19


Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Tue, 16 Jul 2024 09:00:00 +0000 2941 false false Interviews from Asembia’s AXS24 Summit, Part 2 19 Interviews from Asembia’s AXS24 Summit, Part 2 This is the second of two episodes dedicated to Asembia&rsquo;s AXS24 Summit, where we were honored to be a media partner. In this episode, we learn from Sarah Butler, Chief Commercial Officer of A... full 946edd18-f952-45a2-adec-8419ec2c55b8 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/946edd18-f952-45a2-adec-8419ec2c55b8 This is the second of two episodes dedicated to Asembia’s AXS24 Summit, where we were honored to be a media partner. In this episode, we learn from Sarah Butler, Chief Commercial Officer of ADVI Health and Lindsay Greenleaf, JD, MBA, Head of Federal and State Policy for ADVI Health how the 2024 election will impact patient access and affordability. Umar Afridi, Founder and CEO of Foundation Health, summarizes his session, From Opaque to Transparent: Transforming the Way We Pay for Drugs. Finally, we get a few minutes with Joe Boswell, the President of ACCESS Forum, leading an effort to create a network for market access professionals.

ADVI:
Sarah Butler (Chief Commercial Officer)
Lindsey Greenleaf (Consulting and Government Affairs Head)
R&D
Inflation Reduction Act
NCCN Compendia
Part D
CMS
Pharmacy Benefit Managers (PBMs)
Part B
FTC and Office of Inspector General (IG)
FTC's Section 6B study
Foundation Health:Umar Afridi, Founder and CEO
Session: "From Opaque to Transparent: Transforming the Way We Pay for Drugs."
Pharmacy Benefit Managers (PBMs)
Truepill
API platforms
International Access Professional Society:Joe Boswell. President
GenMAV
Asembia

]]> Tue, 04 Jun 2024 09:00:00 +0000 2025 false false Interviews from Asembia's AXS24 Summit, Part 1 of 2 18 Interviews from Asembia's AXS24 Summit, Part 1 of 2 Asembia&rsquo;s AXS24 Summit, a pinnacle of specialty drug and healthcare discussions, concluded earlier this month. We are thrilled to share that our podcast was selected as a media partner for th... full 973d6d71-85ad-4d47-8a97-23a8527386a7 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/973d6d71-85ad-4d47-8a97-23a8527386a7 Asembia’s AXS24 Summit, a pinnacle of specialty drug and healthcare discussions, concluded earlier this month. We are thrilled to share that our podcast was selected as a media partner for this esteemed event. This is the first of two episodes dedicated to AXS24, where Scott and Mark had the opportunity to interview several key speakers and attendees. In this episode, we bring you the insights of Melissa Paige, a seasoned healthcare professional and President of the National Association of Medication Access & Patient Advocacy, who led a session on the Patient Financial Impact of IRA. We also present the perspectives of Renee Rayburg, RPh., VP, Clinical Strategy, Pharmaceutical Strategy Group and Morgan Lee, PhD, MPH, CPH, Senior Director, Research & Strategy, PSG, who are renowned for their study and session on Viewpoints in Specialty Drug Benefit Design.

Melissa Paige, President, (NAMAPA)
University of Virginia Health System
Asembia
Inflation Reduction Act
Dr. Madelaine Feldman
Renee Rayburg, Vice President Specialty Clinical Consulting, Artemetrx, 
Morgan Lee, PhD, Senior Director, PSG
Pharmacy Benefit Managers (PBMs)
GoodRx
2024 Trends in Specialty Drug Benefits Report
Medical terminology referenced in this episode:
Generic ARBs
Multiple Sclerosis
Humira biosimilars
Albuterol inhaler
Email us:comments@prescriptionforbetteraccess.com.
Follow us on X, LinkedIn, YouTube and Threads.

]]> Fri, 24 May 2024 09:00:00 +0000 2140 false false Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research 17 Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research In this episode, we explore the 340B Drug Pricing Program, an essential yet complex component of the American drug supply landscape that aims to enable healthcare entities to offer more affordable ... full 9f0ffaef-ad70-4318-8e68-dbc66d8ac07c https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/9f0ffaef-ad70-4318-8e68-dbc66d8ac07c In this episode, we explore the 340B Drug Pricing Program, an essential yet complex component of the American drug supply landscape that aims to enable healthcare entities to offer more affordable medication to underserved populations. We interview Antonio Ciaccia, a drug pricing and 340B expert who provides an in-depth look at how the program works, its financial incentives, and how stakeholders have exploited this well-intentioned program, all to the detriment of patients.

Medical terminology referenced in this episode:

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Thu, 25 Apr 2024 09:00:00 +0000 2805 false false Interview with Victor Bulto, President, US, Novartis 16 Interview with Victor Bulto, President, US, Novartis In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affo... full d48f9baa-ec95-4ed4-87b6-e49690cb3c7d https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/d48f9baa-ec95-4ed4-87b6-e49690cb3c7d In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affordability for patients. We delve into how the pharmaceutical industry navigates numerous post-FDA approval barriers to launch new drugs and the importance of market access, patient support services, and a commitment by manufacturers to provide patient assistance and other support for patients.

Victor Bulto, President, Novartis

Novartis

FDA

Institute for Clinical and Economic Review (ICER)

American Heart Association (AHA)

Inflation Reduction Act (IRA)

Pharmacy Benefit Manager (PBM)

Medicare

Medical terminology referenced in this episode:

Cell therapy: CART-T 

Radioligand therapy

RNA

Entresto

Molecular glues

Targeted protein degradation

Antisense oligonucleotides

Small interfering RNAs: siRNAs

LDL cholesterol

COVID

Hematological malignancies

Refractory autoimmune diseases

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

]]> Thu, 28 Mar 2024 09:00:00 +0000 2615 false false Biosimilar's Role in Improving Patient Access 15 Biosimilar's Role in Improving Patient Access Biosimilars are entering the market at their fastest pace ever. In this episode, we interview a renowned health economist and an expert consultant in biosimilar distribution and patient support to ... full aa728893-18c9-4373-93e3-563be48cd6ce https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/aa728893-18c9-4373-93e3-563be48cd6ce Biosimilars are entering the market at their fastest pace ever. In this episode, we interview a renowned health economist and an expert consultant in biosimilar distribution and patient support to explore the complex landscape of biosimilars, including examining the hurdles and breakthroughs in achieving acceptance by payers and providers and how best to improve patient access and affordability in a market dominated by established brands.

Dr. Jason Shafrin, Senior Managing Director, Center for Healthcare Economics and Policy at FTI Consulting

Marina Allen, SVP, Fingerpaint Market Access, Patient Support & Access Strategy Leader in Pharma-Biotech

Biosimilars

The Biologics Price Competition and Innovation Act of 2009

PBMs (Pharmacy Benefit Managers)

Medicare Advantage

Humira (biosimilars)

340B program

Inflation Reduction Act

Medicare Part D

"brown bagging and white bagging"

Mark Cuban (CostPlusDrugs)

GoodRx

average sales price (ASP)

electronic health record (EHR) system

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Tue, 27 Feb 2024 10:00:00 +0000 2554 false false 2024 Policy Preview: An Interview with Dr. Mark McClellan 14 2024 Policy Preview: An Interview with Dr. Mark McClellan Scott and Mark welcome Dr. Mark McClellan, a distinguished health policy expert who has served as the Commissioner of the FDA and the Administrator of CMS, to look ahead at the major policy activit... full 8c981a0d-8173-4567-8dbc-ea349e3a94db https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/8c981a0d-8173-4567-8dbc-ea349e3a94db Scott and Mark welcome Dr. Mark McClellan, a distinguished health policy expert who has served as the Commissioner of the FDA and the Administrator of CMS, to look ahead at the major policy activities in 2024. They discuss how the government's role as regulator and purchaser of drugs will influence the drug industry and the patient's ability to access and afford medicines this year. They also discuss the challenges and opportunities for improving public health and the emerging role of artificial intelligence.

Dr. Mark McClellan, PhD, Director and Professor of Business, Medicine and Policy at the Duke-Margolis Center for Health Policy at Duke University

IRA

Medicare Part D

Pharmacy Benefit Managers (PBMs)

Medicare Advantage

FDA commissioner Rob Califf 

The Ryan White HIV/AIDS Program (RWHAP) Part B

Medicare Modernization Act

FDA

FDA's Office of Regulatory Affairs

Centers for Medicare & Medicaid Services (CMS) 

Centers for Disease Control and Prevention (CDC)

Per Member Per Month (PMPM) billing 

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.



]]> Tue, 30 Jan 2024 10:00:00 +0000 2971 false false Episode 13: The Sustainability of Innovation: An Interview with Rachel King, CEO, BIO 13 1 Episode 13: The Sustainability of Innovation: An Interview with Rachel King, CEO, BIO In our 2023 podcasts, there have been a series of revelations about the complexity and unintended consequences related to drug access and affordability. This episode explores the essential underlyi... full 4fbe2daa-befd-4b53-a3fe-4eb9ee6ffc03 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/4fbe2daa-befd-4b53-a3fe-4eb9ee6ffc03 In our 2023 podcasts, there have been a series of revelations about the complexity and unintended consequences related to drug access and affordability. This episode explores the essential underlying tension between the notion that affordability and access are deteriorating while science is advancing so rapidly. We interview Rachel King, CEO of Biotechnology Innovation Organization (BIO), to explore the priorities for the industry and how the challenges related to patient access and affordability could jeopardize innovation for patients today and in the future.

Rachel King, CEO, BIO (Biotechnology Innovation Organization) 

John Crowley, Executive Chairman, Amicus Therapeutics

James Robinson PhD, MPH, Chair, Health Policy and Management Division, Berkeley School of Public Health

The Inflation Reduction Act

Orphan Drug Act

Orphan Cures Act

PBM (pharmacy benefit management)

Medicare Part D

Step Therapy

Cystic Fibrosis Foundation

Therapies mentioned in this episode:

Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! We’re on X as @RX4BetterAccess, LinkedIn and YouTube.

]]> Fri, 22 Dec 2023 10:00:00 +0000 2122 false false Episode 12: How Alternative Funding Programs Exploit Patient Assistance Programs 12 1 Episode 12: How Alternative Funding Programs Exploit Patient Assistance Programs In this episode, we investigate the rise of Alternative Funding Programs (AFPs) that bypass coverage for vital specialty drugs.&nbsp; Kyle Crowell, an expert consultant on AFPs, discusses how payer... full 2567ce5f-0614-4e24-8d7e-00dae86b7a42 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/2567ce5f-0614-4e24-8d7e-00dae86b7a42 In this episode, we investigate the rise of Alternative Funding Programs (AFPs) that bypass coverage for vital specialty drugs.  Kyle Crowell, an expert consultant on AFPs, discusses how payers avoid their responsibility for costs by collaborating with third-party companies to exclude specific drug coverage and directing patients towards manufacturer-sponsored patient assistance programs (PAPs).  Patient advocate, Amy Niles from the PAN Foundation, describes how the mounting tension caused by AFPs are leaving patients to navigate the uncertain waters of their medication coverage and access, potentially risking their health and even their lives.

Kyle Crowell, Principal (Partner) at ZS Associates

Amy Niles, Chief Advocacy and Engagement Officer, PAN Foundation

Patient Assistance programs (PAPs)

Alternative funding programs (AFPs)

“AFP Caution For Patients”

“Pharma faces tough choices as alternative funding programs exploit charitable giving”

Medicare Part D

“AbbVie sues a behind-the-scenes company for exploiting its patient assistance program”

Federal Trade Commission

Carl Schmidt from the HIV and Hepatitis Policy Institute

Copay Accumulator Adjustment Programs Lawsuit

Like this episode and want to hear more? Listen to past episodes here!

Do you have a prescription for better access? Share your comments and episode ideas with us at:
comments@prescriptionforbetteraccess.com.

Find us on social media! We’re on X as @RX4BetterAccess, LinkedIn and YouTube.

 

]]> Thu, 16 Nov 2023 10:00:00 +0000 2400 false false Episode 11: Obesity Week 2023: An Interview with Dr. Angela Fitch, President, Obesity Medicine Association 11 1 Episode 11: Obesity Week 2023: An Interview with Dr. Angela Fitch, President, Obesity Medicine Association Patients are experiencing remarkable weight loss thanks to the new generation of GLP-1&rsquo;s and the downstream health benefits may go well beyond diabetes. In spite of the dramatic results for p... full 00dbb80f-bb3b-4c01-83c3-a3c536b34e26 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/00dbb80f-bb3b-4c01-83c3-a3c536b34e26 Patients are experiencing remarkable weight loss thanks to the new generation of GLP-1’s and the downstream health benefits may go well beyond diabetes. In spite of the dramatic results for patients, insurance plans have started to put up more barriers and are even denying the drugs on a more consistent basis. For this special Obesity Week 2023 episode, we interview Dr. Angela Fitch, President of the Obesity Medicine Association, a faculty member at Harvard Medical School and most recently a Co-Founder and Chief Medical Officer for knownwell, a new obesity-focused primary care company.

Show Notes:

Dr. Angela Fitch, President, OMA

Obesity Week

Obesity Medical Association

Dr. Fitch’s patient care center: Knownwell

Seeking treatment for obesity? Find a clinician here or here.

The Treat and Reduce Obesity Act of 2023

The drugs discussed in this episode: 

An article on the use of “bootlegged” Semaglitude: Demand Rising for 'Bootlegged' Weight-Loss Drug | MedPage Today

Questions or comments?

Email us at comments@prescriptionforbetteraccess.com.

Find us on social media! We’re on X as @RX4BetterAccess, LinkedIn and YouTube.

]]> Tue, 17 Oct 2023 09:00:00 +0000 3324 false false Episode 10: Empowering Employers to Improve Patient Access 10 1 Episode 10: Empowering Employers to Improve Patient Access Employers are discovering this fall that they are expected to shoulder a 6% health insurance increase for 2024. What can employers do to combat the accelerating cost of health insurance without jeo... full d67e4277-e395-426c-a80a-fcb56447be7b https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/d67e4277-e395-426c-a80a-fcb56447be7b Employers are discovering this fall that they are expected to shoulder a 6% health insurance increase for 2024. What can employers do to combat the accelerating cost of health insurance without jeopardizing access to vital drugs? In this podcast episode, we talk with Matt Ohrt, a former HR executive who achieved a 20% reduction in health insurance costs for his employer. Matt has a new book and new company to help other self-funded employers strategically lower their sponsored health insurance costs for 2024 while ensuring employees have optimal access to care and treatments. This is an essential listen for employers seeking to balance cost-efficiency with the provision of comprehensive, high-quality healthcare benefits to their employees.

Matt Ohrt, Co-founder, Chief Healthcare Officer, Self Fund Health

Self Fund Health

Merrill Steel 

How Does Direct Primary Care Work?

Matt Ohrt’s book:  “Save Your Company: Don't Feed the Beast: The Employer Healthcare Success Formula”

Like this episode and want to here more? Check out our past episodes here!

Do you have a prescription for better access? Share your ideas with us at comments@prescriptionforbetteraccess.com


Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

 

 





]]> Fri, 29 Sep 2023 09:00:00 +0000 2505 false false Physician Offices: Fighting for Patient Access 9 1 Physician Offices: Fighting for Patient Access Many of the most beneficial therapies are prescribed or administered within physician offices yet these providers face a multitude of challenges attempting to get authorization and coverage. In thi... full e459a91c-99e0-4f73-ba62-ce697accf49c https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/e459a91c-99e0-4f73-ba62-ce697accf49c Many of the most beneficial therapies are prescribed or administered within physician offices yet these providers face a multitude of challenges attempting to get authorization and coverage. In this podcast, we interview a practice manager who is not only on the frontlines of the battle to help patients but is also an award-winning advocate for access. This episode will explore the barriers faced by providers and their offices and what can be done to win the day-to-day battles with insurance companies and PBM’s so patients can access and remain on treatment.

Julie Baak, Practice Manager, Arthritis Center

Arthritis Center

Rheumatoid Arthritis

Psoriatic Arthritis

Reactive Arthritis

The importance of ultrasound in identifying and differentiating patients with early inflammatory arthritis: a narrative review.

Growing Shortage of Rheumatologists “Very Concerning”

Like this episode and want to here more? Check out our past episodes here!

Do you have a prescription for better access? Share your ideas with us at comments@prescriptionforbetteraccess.com


Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

 

 





]]> Thu, 10 Aug 2023 09:00:00 +0000 2961 false false Washington's Influence on Patient Access 8 1 Washington's Influence on Patient Access This episode delves into the intricate web of Washington's influence on patient access, exploring the multifaceted factors that shape healthcare legislation, policies and their impact on patients, ... full cd3cd742-5645-46a7-aad3-484154b5e76f https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/cd3cd742-5645-46a7-aad3-484154b5e76f This episode delves into the intricate web of Washington's influence on patient access, exploring the multifaceted factors that shape healthcare legislation, policies and their impact on patients, other key stakeholders and drug pricing. With an insightful interview from one of Washington’s top healthcare experts, listeners gain insight to the complexities of legislation, such as the Affordable Care Act and Inflation Reduction Act. This is certainly the “wonkiest” podcast episode as we attempt to provide an understanding of the current landscape of patient access and look ahead to how Washington's decisions will shape the future of patient access.

Lance Grady, Executive Vice President, Avalere

Avalere

Cardinal Health.

Public Health Emergency (PHE) 

AMP cap 

The Affordable Care Act (ACA) 

Innovation Center 

The Inflation Reduction Act (IRA) CMS

Like this episode and want to here more? Check out our past episodes here!

Do you have a prescription for better access? Share your ideas with us at comments@prescriptionforbetteraccess.com


Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

 

 





]]> Thu, 06 Jul 2023 09:00:00 +0000 3233 false false Tackling Copay Accumulators and Maximizers 7 1 Tackling Copay Accumulators and Maximizers In this podcast, we interview a consultant and a leading patient advocate to better understand and explore the challenges of copay accumulator and maximizer programs for specialty drugs. We discuss... full 9fff5c06-c749-4a18-8fb3-65d97f9aaed2 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/9fff5c06-c749-4a18-8fb3-65d97f9aaed2 In this podcast, we interview a consultant and a leading patient advocate to better understand and explore the challenges of copay accumulator and maximizer programs for specialty drugs. We discuss the difference between the two programs and their impact on the various stakeholders including the overwhelming burden placed on patients. We also discuss the legal issues and potential policy changes that could eliminate these programs or minimize their impact on patients. Ultimately, our goal is to shed light on this important issue and identify strategies for improving access to critical medications for patients who need them.

Carl Schmid, Executive Director, HIV And Hepatitis Policy Institute

Lauren Crawford Shaver, Senior Managing Director, FTI Consulting

HIV And Hepatitis Policy Institute

FTI Consulting

President's Advisory Council on HIV/AIDS

National Association of Insurance Commissioners. 

Department of Health and Human Services (HHS)

What are co pay maximizers?

Like this episode and want to here more? Check out our past episodes here!

Do you have a prescription for better access? Share your ideas with us at comments@prescriptionforbetteraccess.com


Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

 

 





]]> Thu, 01 Jun 2023 09:00:00 +0000 2616 false false PBM Perspective: An Interview with Industry Veteran Mesfin Tegenu 6 1 PBM Perspective: An Interview with Industry Veteran Mesfin Tegenu Pharmacy benefit managers (PBM&rsquo;s) manage the drug benefits for millions of Americans and as a result, they can have a positive or negative impact on patient access. Mesfin Tegenu, an early pi... full 153c1449-ad3f-426e-81dd-eab7efba0522 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/153c1449-ad3f-426e-81dd-eab7efba0522 Pharmacy benefit managers (PBM’s) manage the drug benefits for millions of Americans and as a result, they can have a positive or negative impact on patient access. Mesfin Tegenu, an early pioneer in the PBM industry, is interviewed by Scott and Mark and offers his candid perspective on what PBM’s do, their impact on stakeholders and how the PBM industry could evolve over the next few years to better serve patients, employers, health plans and government payers.

Mesfin Tegenu, CEO, Chairman, RxParadigm

RxParadigm

PBM (pharmacy benefit management)

PMS (pharmacy management services)

Vanquishing Hepatitis C: A Remarkable Success Story

Like this episode and want to here more? Check out our past episodes here!

Do you have a prescription for better access? Share your ideas with us at comments@prescriptionforbetteraccess.com


Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)





]]> Tue, 09 May 2023 09:00:00 +0000 2785 false false Understanding ICER: An interview with founder Dr. Steven Pearson 5 1 Understanding ICER: An interview with founder Dr. Steven Pearson In this episode, we interview Dr. Steven Pearson, the founder and President of the Institute for Clinical and Economic Review (ICER). Over the past 16 years, ICER has evolved from a Harvard researc... full 02eb0e33-5e87-4dd5-84e1-4ab7b99dfdaf https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/02eb0e33-5e87-4dd5-84e1-4ab7b99dfdaf In this episode, we interview Dr. Steven Pearson, the founder and President of the Institute for Clinical and Economic Review (ICER). Over the past 16 years, ICER has evolved from a Harvard research program to the independent authority on cost-effectiveness and value of new drugs. Dr. Pearson has been an advocate of “Fair Pricing for Fair Access” and in January 2023, ICER published their 2nd Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage.

Dr. Steven Pearson, Founder, President, Institute for Clinical and Economic Review (ICER)


Institute for Clinical and Economic Review (ICER)

Barriers to Fair Access Report 

Gross-to-Net Bubble

Like this episode and want to hear more? Check out our past episodes here!

Do you have a prescription for better access? Share your ideas with us at comments@prescriptionforbetteraccess.com

Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)





]]> Tue, 18 Apr 2023 14:00:00 +0000 2836 false false Understanding Drug Pricing: An Interview with Health Economist James Robinson 4 1 Understanding Drug Pricing: An Interview with Health Economist James Robinson In this foundational episode about drug pricing, we interview Dr. Jamie Robinson, the Leonard D. Schaeffer Professor of Health Economics, and Director of the Berkeley Center for Health Technology a... full d5ca6d9f-3437-4a02-9bd9-7c6205c1ba8e https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/d5ca6d9f-3437-4a02-9bd9-7c6205c1ba8e In this foundational episode about drug pricing, we interview Dr. Jamie Robinson, the Leonard D. Schaeffer Professor of Health Economics, and Director of the Berkeley Center for Health Technology at the University of California, Berkeley. Dr. Robinson is the author of 3 books and 150 peer-reviewed articles on health economics and drug pricing.

James Robinson PhD, MPH, Chair, Health Policy and Management Division, Berkeley School of Public Health

Clarification on term “drug pricing”:

Nomenclature for this episode refers to the price of drugs from wholesale acquisition or list price. Other prices include the price of patient cost sharing or hospital/physician administered medication.

Biosimilars

Generics Versus Biosimilars

PBMs (Pharmacy Benefit Managers)

Do you have a prescription for better access? Share your ideas and show topics with us at comments@prescriptionforbetteraccess.com

Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)





]]> Tue, 28 Mar 2023 09:00:00 +0000 2791 false false Breaking Down Barriers: An Interview with Peyton Howell 3 1 Breaking Down Barriers: An Interview with Peyton Howell This episode features an interview with Peyton Howell discussing the evolution of patient access over the past three decades, the creation of the hub industry, and the continuing challenges faced b... full 56d04984-0d9d-47de-8594-071b74ad2340 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/56d04984-0d9d-47de-8594-071b74ad2340 This episode features an interview with Peyton Howell discussing the evolution of patient access over the past three decades, the creation of the hub industry, and the continuing challenges faced by pharma companies and service providers in supporting patient access to medications.

Peyton Howell, Chief Operating and Growth Officer, Parexel

Parexel

Lash Group

Genentech

Biologics

How Automation Is Transforming Healthcare Jobs

Do you have a prescription for better access? Share your ideas and show topics with us at comments@prescriptionforbetteraccess.com

Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

]]> Tue, 07 Mar 2023 10:00:00 +0000 2366 false false Patient Voices: The Value and Challenges of Access 2 1 Patient Voices: The Value and Challenges of Access In this episode, co-hosts Mark Hansan and Dr. Scott Howell interview two patients who share their personal journeys, how medicine has helped them, their challenges related to access, and how both a... full 450507f1-6cf9-40ef-a1c6-eff4de9f2b9c https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/450507f1-6cf9-40ef-a1c6-eff4de9f2b9c In this episode, co-hosts Mark Hansan and Dr. Scott Howell interview two patients who share their personal journeys, how medicine has helped them, their challenges related to access, and how both are making a difference for patients.

Donna Cryer, JD, CEO, Founder of the Global Liver Institute

Reid Jewitt Smith, Ph.D., Patient Advocate and Career Educator

Global Liver Institute

Cystic Fibrosis

Vertex Pharmaceuticals 

Medications discussed in this episode:

Decoupling: What is it, and how could it reshape American health care?

Do you have a prescription for better access?

Share your ideas and show topics with us at

comments@prescriptionforbetteraccess.com

Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

]]> Wed, 15 Feb 2023 10:00:00 +0000 2816 false false 2023: Looking Ahead in Patient Access 1 1 2023: Looking Ahead in Patient Access In this episode Mark and Scott interview Dave Moules, former Pfizer SVP, Payer and Channel Access to look at the year ahead in patient access. David Moules, former Pfizer SVP, Payer and Channel Ac... full 29830113-7248-4d34-9bd1-89849f52fc36 https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/29830113-7248-4d34-9bd1-89849f52fc36 In this episode Mark and Scott interview Dave Moules, former Pfizer SVP, Payer and Channel Access to look at the year ahead in patient access.

David Moules, former Pfizer SVP, Payer and Channel Access

The Inflation Reduction Act

The Affordable Care Act 

340B Drug Pricing Program

Insulin Affordability and the Inflation Reduction Act

Do you have a prescription for better access?

Share your ideas with us at comments@prescriptionforbetteraccess.com

Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

]]> Tue, 31 Jan 2023 16:30:00 +0000 3081 false false Podcast Preview: Getting to Know Your Co-hosts 0 1 Podcast Preview: Getting to Know Your Co-hosts In this preview episode, you will have the opportunity to get to know co-hosts Mark Hansan and Dr. Scott Howell and why they have come together to launch the interview-focused podcast to help impro... full dd2ea818-c32e-4843-90e6-776434c80a5f https://feeds.resonaterecordings.com/hosting/prescription-for-better-access/dd2ea818-c32e-4843-90e6-776434c80a5f In this preview episode, you will have the opportunity to get to know co-hosts Mark Hansan and Dr. Scott Howell and why they have come together to launch the interview-focused podcast to help improve patient access to medicines.

Mark Hansan, Co-founder and Executive Chairman, CareMetx, LLC

Dr. Scott Howell, Healthcare and biopharma teacher, researcher, and advisor

Prescription For Better Access website

Do you have a prescription for better access?

Share your ideas with us at comments@prescriptionforbetteraccess.com

Follow us on social media! We’re on YouTube, LinkedIn and @RX4BetterAccess (X)

]]> Mon, 23 Jan 2023 10:00:00 +0000 972 false false